R&D Strategies of the Top 30 Pharmaceutical Companies
Strategic Management
The pharmaceutical industry is currently undergoing dramatic changes: as the market looks to consolidate, there has been another wave of large-scale mergers and acquisitions, with companies eager to maintain positions of strength in an increasingly competitive market. The strength of R&D and healthy product pipelines are key factors in ensuring competitive advantage.
Comprehensive analysis of the top 30 Pharma Companies
This report provides an insight into the R&D strategies of individual companies, including their collaborative R&D activities and the increasingly common M&A deals and alliances. It also suggests potential replacement products for marketed drugs facing impending patent expiry. Profiles of each of the top 30 companies include:-
Establish your own company's strengths and weaknesses in R&D...
This report will enable you to examine your organisation's position in the current marketplace by answering the following questions: -
By providing commentary on the strengths and weaknesses of the pipeline portfolios in relation to competitors, R & D Strategies of the Top 30 Pharma Companies is guaranteed to be an essential guide and reference tool for you and your colleagues in R&D.
Published: February 2001
Pages: 343
Ref: BS1083E
Price: £695/$1,460/¥167,000
For further information about this report, please contact our Customer Helpdesk on:
Tel: +44 (0)20 8332 8965 / 66
Fax: +44 (0)20 8332 8992
E-mail: [email protected]
Executive summary
Scope and methodology
Abbrieviations
Chapter 1: The R&D challenge
1.1 Introduction
1.1.1 The cost of R&D
1.1.2 The productivity problem
1.1.3 The time factor
1.1.4 Opportunities for growth
1.2 Trends in R&D
1.2.1 Focused R&D pipelines
1.2.2 Strategic outsourcing, alliances and in-licensing
1.2.3 The genomics factor
1.2.4 The impact of new discovery technologies
1.2.5 Optimisation of clinical development
1.3 Mergers and "mega-pharmas"
1.4 Trends in healthcare management
1.4.1 The role of niche products
1.5 The new R&D model
Chapter 2: Company profiles
2.1 Abbott
financial data
patent expirations
2.1.1 R&D pipeline
2.1.2 R&D pipeline by therapeutic category
2.1.3 Licensed products and collaborations
2.1.4 Overview and highlights
2.2 American Home Products
financial data
patent expirations
2.2.1 R&D pipeline
2.2.2 R&D pipeline by therapeutic category
2.2.3 Licensed products and collaborations
2.2.4 Overview and highlights
2.3 Akzo Nobel
financial data
patent expirations
2.3.1 R&D pipeline
2.3.2 R&D pipeline by therapeutic category
2.3.3 Licensed products and collaborations
2.3.4 Overview and highlights
2.4 Amgen
financial data
patent expirations
2.4.1 R&D pipeline
2.4.2 R&D pipeline by therapeutic category
2.4.3 Licensed products and collaborations
2.4.4 Overview and highlights
2.5 AstraZeneca
financial data
patent expirations
2.5.1 R&D pipeline
2.5.2 R&D pipeline by therapeutic category
2.5.3 Licensed products and collaborations
2.5.4 Overview and highlights
2.6 Aventis
financial data
patent expirations
2.6.1 R&D pipeline
2.6.2 R&D pipeline by therapeutic category
2.6.3 Licensed products and collaborations
2.6.4 Overview and highlights
2.7 Bayer AG
financial data
patent expirations
2.7.1 R&D pipeline
2.7.2 R&D pipeline by therapeutic category
2.8.3 Licensed products and collaborations
2.9.4 Overview and highlights
2.8 Boehringer Ingelheim
financial data
patent expirations
2.8.1 R&D pipeline
2.8.2 R&D pipeline by therapeutic category
2.8.3 Licensed products and collaborations
2.8.4 Overview and highlights
2.9 Bristol-Myers Squibb
financial data
patent expirations
2.9.1 R&D pipeline
2.9.2 R&D pipeline by therapeutic category
2.9.3 Licensed products and collaborations
2.9.4 Overview and highlights
2.10 Eisai
financial data
patent expirations
2.10.1 R&D pipeline
210.2 R&D pipeline by therapeutic category
210.3 Licensed products and collaborations
210.4 Overview and highlights
2.11 Fujisawa
financial data
patent expirations
2.11.1 R&D pipeline
2.11.2 R&D pipeline by therapeutic category
2.11.3 Licensed products and collaborations
2.11.4 Overview and highlights
2.12 GlaxoSmithKline
financial data
patent expirations
2.12.1 R&D pipeline
2.12.2 R&D pipeline by therapeutic category
2.12.3 Licensed products and collaborations
2.12.4 Overview and highlights
2.13 Johnson & Johnson
financial data
patent expirations
2.13.1 R&D pipeline
2.13.2 R&D pipeline by therapeutic category
2.13.3 Licensed products and collaborations
2.13.4 Overview and highlights
2.14 Knoll AG
financial data
patent expirations
2.14.1 R&D pipeline
2.14.2 R&D pipeline by therapeutic category
2.14.3 Licensed products and collaborations
2.14.4 Overview and highlights
2.15 Eli Lilly
financial data
patent expirations
2.15.1 R&D pipeline
2.15.2 R&D pipeline by therapeutic category
2.15.3 Licensed products and collaborations
2.15.4 Overview and highlights
2.16 Merck & Co
financial data
patent expirations
2.16.1 R&D pipeline
2.16.2 R&D pipeline by therapeutic category
2.16.3 Licensed products and collaborations
2.17 Merck KGaA
financial data
patent expirations
2.17.1 R&D pipeline
2.17.2 R&D pipeline by therapeutic category
2.17.3 Licensed products and collaborations
2.17.4 Overview and highlights
2.18 Novartis
financial data
patent expirations
2.18.1 R&D pipeline
2.18.2 R&D pipeline by therapeutic category
2.18.3 Licensed products and collaborations
2.18.4 Overview and highlights
2.19 Novo Nordisk
financial data
patent expirations
2.19.1 R&D pipeline
2.19.2 R&D pipeline by therapeutic category
2.19.3 Licensed products and collaborations
2.19.4 Overview and highlights
2.20 Pfizer
financial data
patent expirations
2.20.1 R&D pipeline
2.20.2 R&D pipeline by therapeutic category
2.20.3 Licensed products and collaborations
2.20.4 Overview and highlights
2.21 Pharmacia Group
financial data
patent expirations
2.21.1 R&D pipeline
2.21.2 R&D pipeline by therapeutic category
2.21.3 Licensed products and collaborations
2.21.4 Overview and highlights
2.22 Roche
financial data
patent expirations
2.22.1 R&D pipeline
2.22.2 R&D pipeline by therapeutic category
2.22.3 Licensed products and collaborations
2.22.4 Overview and highlights
2.23 Sankyo
financial data
patent expirations
2.23.1 R&D pipeline
2.23.2 R&D pipeline by therapeutic category
2.23.3 Licensed products and collaborations
2.23.4 Overview and highlights
2.24 Sanofi-Synth�labo
financial data
patent expirations
2.24.1 R&D pipeline
2.24.2 R&D pipeline by therapeutic category
2.24.3 Licensed products and collaborations
2.24.4 Overview and highlights
2.25 Schering AG
financial data
patent expirations
2.25.1 R&D pipeline
2.25.2 R&D pipeline by therapeutic category
2.25.3 Licensed products and collaborations
2.25.4 Overview and highlights
2.26 Schering-Plough
financial data
patent expirations
2.26.1 R&D pipeline
2.26.2 R&D pipeline by therapeutic category
2.26.3 Licensed products and collaborations
2.26.4 Overview and highlights
2.27 Shionogi
financial data
patent expirations
2.27.1 R&D pipeline
2.27.2 R&D pipeline by therapeutic category
2.27.3 Licensed products and collaborations
2.27.4 Overview and highlights
2.28 Taisho
financial data
patent expirations
2.28.1 R&D pipeline
2.28.2 R&D pipeline by therapeutic category
2.28.3 Licensed products and collaborations
2.28.4 Overview and highlights
2.29 Takeda
financial data
patent expirations
2.29.1 R&D pipeline
2.29.2 R&D pipeline by therapeutic category
2.29.3 Licensed products and collaborations
2.29.4 Overview and highlights
2.30 Yamanouchi
financial data
patent expirations
2.30.1 R&D pipeline
2.30.2 R&D pipeline by therapeutic category
2.30.3 Licensed products and collaborations
2.30.4 Overview and highlights
Chapter 3: Summary Tables
Chapter 4: Directory
© PJB Publications Ltd. 2001
All rights reserved.